Maria Alma Rodriguez

发表

Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐Hodgkin lymphomas

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2013, British journal of haematology.

Paclitaxel plus high‐dose cyclosphosphamide with G‐CSF support in patients with relapsed and refractory aggressive non‐Hodgkin's lymphoma

P. Mclaughlin, F. Cabanillas, A. Younes, 1998, British journal of haematology.

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2010, British journal of haematology.

Ultra–low‐dose radiotherapy for definitive management of ocular adnexal B‐cell lymphoma

Michael L. Wang, Y. Oki, B. Esmaeli, 2017, Head and Neck.

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

T. Pan, Y. Oki, A. Younes, 2014, British journal of haematology.

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

P. Mclaughlin, J. Manning, L. Medeiros, 2003, Cancer.

Primary adrenal natural killer/T‐cell nasal type lymphoma: First case report in adults

M. Routbort, F. C. Holsinger, M. Thompson, 2007, American journal of hematology.

Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia

Susan O'Brien, Jorge Cortes, Guillermo Garcia-Manero, 2006, Cancer.

Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

Dan Jones, Maria A. Rodriguez, P. Mclaughlin, 2007, British journal of haematology.

Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2003, Cancer.

Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2013, British journal of haematology.

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

Michael L. Wang, Y. Oki, F. Turturro, 2014, British journal of haematology.

Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma

F. Cabanillas, J. Cox, R. Wilder, 2001, Cancer.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hodgkin's Disease in Patients Infected with Human Immunodeficiency Virus: Frequency, Presentation and Clinical Outcome

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Leukemia & lymphoma.

Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial

Jeffrey E. Lee, R. Winn, Yu Shen, 1999, Annals of Internal Medicine.

A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma.

E. Shpall, D. Chihara, J. Westin, 2023, Blood advances.

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

S. Tucker, W. Velasquez, P. Mclaughlin, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab

L. Gordon, A. LaCasce, A. Vanderplas, 2013, Cancer.

Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era

L. Gordon, A. LaCasce, A. Vanderplas, 2012, Cancer.

The clinical significance of molecular response in indolent follicular lymphomas.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 1998, Blood.

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.

K. Kliche, M. Andreeff, S. Tucker, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma

Michael L. Wang, Y. Oki, P. Mclaughlin, 2013, British journal of haematology.

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.

W. Velasquez, P. Mclaughlin, F. Cabanillas, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International prognostic index‐based outcomes for diffuse large B‐cell lymphomas

S. Tucker, F. Cabanillas, L. Medeiros, 2002, Cancer.

Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase.

F. Cabanillas, F. Cabanillas, R. Luthra, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Conditioning regimens Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

N. Ueno, B. Andersson, L. Fayad, 2005 .

Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 2000, Seminars in oncology.

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

A. Alizadeh, D. Kurtz, Y. Oki, 2022, Blood advances.

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

C. Flowers, Linghua Wang, S. Parmar, 2022, Blood.

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

P. Mclaughlin, J. Manning, F. Cabanillas, 2000, Bone Marrow Transplantation.

Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma

R. Gascoyne, J. Winter, R. Pytlík, 2009, Cancer.

Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.

S. Tucker, J. Cox, F. Cabanillas, 2001, International journal of radiation oncology, biology, physics.

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next‐generation sequencing approach

Maria A. Rodriguez, Y. Oki, V. Carlton, 2015, British journal of haematology.

Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant

Michael L. Wang, K. Rezvani, E. Shpall, 2022, British journal of haematology.

Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies.

L. Fuller, J. Cox, B. Brown, 1997, International journal of radiation oncology, biology, physics.

Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project

L. Gordon, A. LaCasce, Allison Crosby-Thompson, 2015, Cancer.

Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy.

L. Fuller, P. Mclaughlin, F. Cabanillas, 1994, Seminars in hematology.

Small noncleaved cell lymphoma in adults: superior results for stages I-III disease.

S. Tucker, W. Velasquez, P. Mclaughlin, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.

S. Tucker, W. Velasquez, P. Mclaughlin, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

S. Verstovsek, N. Dang, R. Champlin, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database

L. Gordon, A. LaCasce, Allison Crosby-Thompson, 2013, British journal of haematology.

Comparison of referring and final pathology for patients with T‐cell lymphoma in the National Comprehensive Cancer Network

L. Gordon, A. LaCasce, Allison Crosby-Thompson, 2014, Cancer.

Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981.

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma

J. Cox, F. Cabanillas, B. Andersson, 2004, Bone Marrow Transplantation.

Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 1999, Blood.

Phase II Study of Paclitaxel in Combination with Mitoxantrone and Ifosfamide/Mesna for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma after Failure to Cytarabine/Cisplatin Combination

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Investigational New Drugs.

Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.

W. Velasquez, P. Mclaughlin, F. Cabanillas, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease.

L. Fuller, F. Cabanillas, F. Cabanillas, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Usage of erythropoiesis‐stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia

Maria A. Rodriguez, A. Buzdar, A. Ferrajoli, 2011, Cancer.

A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.

W. Velasquez, P. Mclaughlin, F. Cabanillas, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.